PureTech Health (PRTC.L) Stock Price

PureTech Health Price

Delisted·Jun 19, 2026
1.74USD-0.0066 (-0.38 %)
Last traded price

Revenue at PureTech Health has contracted by 4.1% per year over the past 12 years to 4.83 M USD. Earnings per share have grown at 9.5% per year over the last 7 years. For PureTech Health, the net margin of 1,108.3% is up versus 50.9% a few years ago. The consensus 12-month price target for PureTech Health is 691.31 USD, about 39,595.7% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 788% above its 52-week low.

PureTech Health stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of PureTech Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PureTech Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PureTech Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PureTech Health Stock Price History
DatePureTech Health Price
6/19/20261.74 USD
6/18/20261.75 USD
6/17/20261.73 USD
6/16/20261.75 USD
6/15/20261.77 USD
6/12/20261.77 USD
6/11/20261.71 USD
6/10/20261.64 USD
6/9/20261.66 USD
6/8/20261.67 USD
6/5/20261.69 USD
6/4/202616.89 USD
6/3/202616.63 USD
6/2/202617.84 USD
6/1/202618.01 USD
5/29/202618.51 USD
5/28/202618.05 USD
5/27/202618.32 USD
5/26/202618.60 USD
5/22/202617.53 USD
5/21/202617.40 USD
5/20/202617.35 USD
5/19/202617.08 USD
5/18/202616.73 USD
5/15/202617.39 USD
5/14/202617.96 USD
5/13/20260.24 USD
5/12/20260.23 USD
5/11/20260.24 USD
5/8/20260.23 USD
5/7/20260.23 USD
5/6/20260.23 USD
5/5/20260.23 USD
5/4/20260.23 USD
5/1/20260.25 USD
4/30/20260.23 USD
4/29/20260.24 USD
4/28/20260.25 USD
4/27/20260.23 USD
4/24/20260.23 USD
4/23/20260.24 USD
4/22/20260.24 USD
4/21/20260.24 USD
4/20/20260.25 USD
4/17/20260.25 USD
4/16/20260.25 USD
4/15/20260.25 USD
4/14/20260.24 USD
4/13/20260.24 USD
4/10/20260.22 USD
4/9/20260.22 USD
4/8/20260.21 USD
4/7/20260.21 USD
4/6/20260.21 USD
4/2/20260.21 USD
4/1/20260.20 USD
3/31/20260.20 USD
3/30/20260.20 USD
3/27/20260.21 USD
3/26/20260.21 USD
3/25/20260.22 USD
3/24/20260.21 USD
3/23/20260.21 USD
3/20/20260.22 USD
3/19/20260.22 USD
3/18/20261.60 USD
3/17/20261.62 USD
3/16/20261.61 USD
3/13/20261.62 USD
3/12/20261.66 USD
3/11/20261.68 USD
3/10/20261.68 USD
3/9/20261.64 USD
3/6/20261.66 USD
3/5/20261.67 USD
3/4/20261.69 USD
3/3/20261.66 USD
3/2/20261.66 USD
2/27/20261.66 USD
2/26/20261.65 USD
2/25/20261.66 USD
2/24/20261.67 USD
2/23/20261.67 USD
2/20/20261.70 USD
2/19/20261.67 USD
2/18/20261.69 USD
2/17/20261.73 USD
2/16/20261.71 USD
2/13/20261.71 USD
2/12/20261.71 USD
2/11/20261.73 USD
2/10/20261.73 USD
2/9/20261.69 USD
2/6/20261.70 USD
2/5/20261.73 USD
2/4/20261.78 USD
2/3/20261.78 USD
2/2/20261.81 USD
1/30/20261.79 USD
1/29/20261.79 USD
1/28/20261.81 USD
1/27/20261.82 USD
1/26/20261.86 USD
1/23/20261.80 USD
1/22/20261.81 USD
1/21/20261.79 USD
1/20/20261.75 USD
1/19/20261.81 USD
1/16/20261.83 USD
1/15/20261.81 USD
1/14/20261.80 USD
1/13/20261.79 USD
1/12/20261.76 USD
1/9/20261.74 USD
1/8/20261.71 USD
1/7/20261.74 USD
1/6/20261.70 USD
1/5/20261.67 USD
1/2/20261.68 USD
12/31/20251.68 USD
12/30/20251.71 USD
12/29/20251.73 USD
12/24/20251.69 USD
12/23/20251.70 USD
12/22/20251.69 USD
12/19/20251.70 USD
12/18/20251.67 USD
12/17/20251.62 USD
12/16/20251.62 USD
12/15/20251.64 USD
12/12/20251.64 USD
12/11/20251.65 USD
12/10/20251.65 USD
12/9/20251.67 USD
12/8/20251.66 USD
12/5/20251.63 USD
12/4/20251.63 USD
12/3/20251.61 USD
12/2/20251.63 USD
12/1/20251.67 USD
11/28/20251.68 USD
11/27/20251.69 USD
11/26/20251.67 USD
11/25/20251.66 USD
11/24/20251.65 USD
11/21/20251.62 USD
11/20/20251.66 USD
11/19/20251.67 USD
11/18/20251.60 USD
11/17/20251.63 USD
11/14/20251.65 USD
11/13/20251.67 USD
11/12/20251.68 USD
11/11/20251.67 USD
11/10/20251.65 USD
11/7/20251.66 USD
11/6/20251.68 USD
11/5/20251.71 USD
11/4/20251.72 USD
11/3/20251.73 USD
10/31/20251.77 USD
10/30/20251.79 USD
10/29/20251.80 USD
10/28/20251.79 USD
10/27/20251.79 USD
10/24/20251.79 USD
10/23/20251.79 USD
10/22/20251.79 USD
10/21/20251.79 USD
10/20/20251.80 USD
10/17/20251.78 USD
10/16/20251.78 USD
10/15/20251.76 USD
10/14/20251.76 USD
10/13/20251.78 USD
10/10/20251.76 USD
10/9/20251.81 USD
10/8/20251.80 USD
10/7/20251.83 USD
10/6/20251.87 USD
10/3/20251.90 USD
10/2/20251.89 USD
10/1/20251.86 USD
9/30/20251.78 USD
9/29/20251.74 USD
9/26/20251.67 USD
9/25/20251.69 USD
9/24/20251.71 USD
9/23/20251.68 USD
9/22/20251.68 USD
9/19/20251.62 USD
9/18/20251.42 USD
9/17/20251.44 USD
9/16/20251.45 USD
9/15/20251.50 USD
9/12/20251.52 USD
9/11/20251.53 USD
9/10/20251.55 USD
9/9/20251.56 USD
9/8/20251.58 USD
9/5/20251.57 USD
9/4/20251.57 USD
9/3/20251.55 USD
9/2/20251.55 USD
9/1/20251.63 USD
8/29/20251.67 USD
8/28/20251.70 USD
8/27/20251.79 USD
8/26/20251.78 USD
8/22/20251.86 USD
8/21/20251.80 USD
8/20/20251.79 USD
8/19/20251.80 USD
8/18/20251.80 USD
8/15/20251.79 USD
8/14/20251.75 USD
8/13/20251.79 USD
8/12/20251.71 USD
8/11/20251.72 USD
8/8/20251.77 USD
8/7/20251.79 USD
8/6/20251.78 USD
8/5/20251.83 USD
8/4/20251.84 USD
8/1/20251.84 USD
7/31/20251.90 USD
7/30/20251.94 USD
7/29/20251.93 USD
Access this data via the Eulerpool API
Get Free API Key

PureTech Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
15.62 M USD
-197.81 M USD
-50.35 M USD
Jan 1, 2023
3.33 M USD
-146.20 M USD
-65.70 M USD
Jan 1, 2024
4.83 M USD
-136.10 M USD
53.51 M USD
Jan 1, 2025 (e)
3.70 M USD
-2.22 M USD
-154.45 M USD
Jan 1, 2026 (e)
10.76 M USD
-6.46 M USD
-137.17 M USD
Jan 1, 2027 (e)
20.41 M USD
-12.25 M USD
-102.41 M USD
Jan 1, 2028 (e)
35.73 M USD
-21.44 M USD
-48.18 M USD
Jan 1, 2029 (e)
889.61 M USD
0.00 USD
0.00 USD

PureTech Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 28, 2026, 10:58 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201420152016201720182019202020212022202320242025e2026e2027e2028e2029e
2.0011.004.002.0020.009.0011.0017.0015.003.004.003.0010.0020.0035.00889.00
-75.00450.00-63.64-50.00900.00-55.0022.2254.55-11.76-80.0033.33-25.00233.33100.0075.002,440.00
750.00136.36375.00750.0075.00166.67136.3688.24100.00500.00375.00100.00100.00100.00100.00100.00
15.0015.0015.0015.0015.0015.0015.0015.0015.0015.0015.003.0010.0020.0035.00889.00
-17.00-43.00-73.00-115.00-104.00-135.00-119.00-150.00-197.00-146.00-136.00-2.00-6.00-12.00-21.00–
-850.00-390.91-1,825.00-5,750.00-520.00-1,500.00-1,081.82-882.35-1,313.33-4,866.67-3,400.00-66.67-60.00-60.00-60.00–
-41.00-39.00-48.0026.00-43.00421.005.00-60.00-50.00-65.0053.00-154.00-137.00-102.00-48.00–
925.00-4.8823.08-154.17-265.38-1,079.07-98.81-1,300.00-16.6730.00-181.54-390.57-11.04-25.55-52.94–
227.25118.10229.51238.92273.85283.43292.86286.59284.76276.30256.03256.03256.03256.03256.03256.03
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PureTech Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PureTech Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PureTech Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PureTech Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PureTech Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PureTech Health stock margins

The PureTech Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PureTech Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PureTech Health.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.01 %
-1,015.55 %
50.89 %
Jan 1, 2021
100.01 %
-864.17 %
-348.25 %
Jan 1, 2022
100.01 %
-1,266.53 %
-322.41 %
Jan 1, 2023
100.01 %
-4,390.36 %
-1,972.88 %
Jan 1, 2024
100.01 %
-2,818.87 %
1,108.33 %
Jan 1, 2025 (e)
100.01 %
-60.00 %
-4,179.51 %
Jan 1, 2026 (e)
100.01 %
-60.00 %
-1,274.42 %
Jan 1, 2027 (e)
100.01 %
-60.00 %
-501.65 %

PureTech Health Stock Revenue, EBIT, Earnings per Share

The PureTech Health earnings per share therefore indicates how much revenue PureTech Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.04 USD
-0.41 USD
0.02 USD
Jan 1, 2021
0.06 USD
-0.52 USD
-0.21 USD
Jan 1, 2022
0.05 USD
-0.69 USD
-0.18 USD
Jan 1, 2023
0.01 USD
-0.53 USD
-0.24 USD
Jan 1, 2024
0.02 USD
-0.53 USD
0.21 USD
Jan 1, 2025 (e)
0.01 USD
-0.01 USD
-0.60 USD
Jan 1, 2026 (e)
0.04 USD
-0.03 USD
-0.54 USD
Jan 1, 2027 (e)
0.08 USD
-0.05 USD
-0.40 USD

PureTech Health business model & stock analysis

PureTech Health is an innovative company specializing in the development of novel medical therapies and solutions. The company was founded in 2002 by Daphne Zohar and is headquartered in Boston, USA. PureTech Health is listed on the London Stock Exchange and has become one of the leading biotech companies in recent years. The company's business model is based on identifying medical needs and developing new products and therapies to meet those needs. It utilizes cutting-edge technologies to work quickly and effectively. Research and development are closely linked in an iterative process. PureTech Health's main focus is oncology, specifically developing immune-oncology therapies that target the patient's immune system to strengthen their body's defense against cancer cells. The company has also developed an innovative drug discovery system that combines nanotechnology and artificial intelligence. Another focus area for PureTech Health is gastroenterology. The company has developed a novel technology that selectively releases medical substances in the intestine, allowing targeted treatment of gastrointestinal diseases. PureTech Health has also developed a new method for diagnosing colorectal cancer based on the identification of bacteria in feces. In the field of neuropsychiatric disorders, the company has promising research results. It has developed a new technology that enables targeted manipulation of the central nervous system, allowing for the treatment of conditions such as depression, anxiety disorders, and ADHD. To this end, PureTech Health has developed a novel nasal spray that delivers the active ingredients directly to the brain. Biosensing is another area of focus for PureTech Health. The company has developed a novel technology that allows for the measurement of medical parameters such as blood sugar, cholesterol, and blood pressure. The sensors are available in the form of patches or other wearable devices and are easy and convenient to use. This technology is intended to help older people and those with chronic illnesses better monitor their health. Overall, PureTech Health is an innovative biotech company that is constantly seeking novel medical solutions. It operates in various areas and has promising products and therapies in the pipeline. With its close integration of research and development, PureTech Health is able to quickly and flexibly respond to market changes. With strong management and an experienced team, the company is well-positioned for further growth in the coming years.

PureTech Health SWOT Analysis

Strengths

PureTech Health PLC has a diverse portfolio of innovative healthcare companies focused on developing important solutions for unmet medical needs. The company has a strong track record of transforming scientific discoveries into valuable therapies that address major healthcare challenges. PureTech's approach of building and growing companies from within allows for significant control and alignment with its objectives.

Additionally, PureTech possesses a robust global network of academic, clinical, and industry partnerships. These collaborations enable access to cutting-edge research, expertise, and resources, strengthening the company's ability to identify and develop promising healthcare technologies.

Weaknesses

One weakness of PureTech Health PLC is its reliance on the success of its portfolio companies. If any of these companies fail to achieve their anticipated milestones or face regulatory or market challenges, it could have a negative impact on PureTech's overall financial performance and reputation.

Furthermore, as a company engaged in the healthcare industry, PureTech is subject to stringent regulations and potential legal and ethical controversies. This can create challenges in product development, manufacturing, and commercialization, increasing compliance costs and potentially delaying revenue generation.

Opportunities

PureTech Health PLC operates in an industry that presents substantial growth opportunities. The increasing global demand for innovative healthcare solutions, driven by demographic shifts and rising healthcare costs, creates a favorable market for the company's products and services.

Moreover, advancements in scientific research and technology provide an opportune environment for PureTech to leverage its expertise and create novel therapies. Strategic collaborations with academia, research institutions, and industry leaders offer avenues for accessing breakthrough discoveries and expanding the company's pipeline.

Threats

The healthcare industry is highly competitive, and PureTech Health PLC faces the risk of being outpaced by competitors with similar or superior capabilities. The presence of well-established pharmaceutical and biotechnology companies, as well as the emergence of new players, poses a threat to PureTech's market share and growth prospects.

Additionally, regulatory hurdles and approval processes can create prolonged timelines and uncertainties in bringing products to market. Delays in obtaining necessary approvals or changing regulatory requirements may hinder PureTech's ability to capitalize on market opportunities effectively.

PureTech Health Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

PureTech Health historical P/E ratio, EBIT multiple, and P/S ratio

PureTech Health annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PureTech Health shares outstanding

The number of shares of PureTech Health was 256.03 M in 2025. This indicates how many shares PureTech Health is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
292.86 M Stocks
Jan 1, 2021
286.59 M Stocks
Jan 1, 2022
284.76 M Stocks
Jan 1, 2023
276.30 M Stocks
Jan 1, 2024
256.03 M Stocks
Jan 1, 2025 (e)
256.03 M Stocks
Jan 1, 2026 (e)
256.03 M Stocks
Jan 1, 2027 (e)
256.03 M Stocks

Current PureTech Health forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy80.00 % (4)
Hold20.00 % (1)
Sell0.00 % (0)
12M Price Target
0.00
Last Price
1.74
Currency
USD
12M Return Potential
-100.00 %
LTM Return
0 %

PureTech Health Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/25/2024-0.30USD16.16 MUSD2023 Q4
8/25/2022-0.20USD8.31 MUSD2022 Q2
4/26/2022-0.20USD8.13 MUSD2021 Q4
8/24/2021-0.15USD5.07 MUSD2021 Q2
4/15/2021-0.20USD14.21 MUSD2020 Q4
8/27/2020-0.10USD10.15 MUSD2020 Q2
4/9/2020-USD37.56 MUSD2019 Q4
8/27/2019-0.20USD15.22 MUSD2019 Q2
4/24/2019-0.20USD13.19 MUSD2018 Q4
9/11/2018-0.20USD1.01 MUSD2018 Q2

EESG©

Eulerpool ESG Scorecard© for the PureTech Health stock

68/100
78
Environment
99
Social
28
Governance
E

Environment

20
Scope 1 - Direct Emissions3.2
Scope 2 - Indirect emissions from purchased energy60.1
Scope 3 - Indirect emissions within the value chain75.6
Total CO₂ emissions63.3
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PureTech Health shareholder structure

% Name
16.01852%
INVESCO Asset Management Limited
INVESCO Asset Management Limited
6.13475%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
5.69079%
Citigroup Global Markets Ltd.
Citigroup Global Markets Ltd.
5.63821%
Lansdowne Partners (UK) LLP
Lansdowne Partners (UK) LLP
4.54086%
Baillie Gifford & Co.
Baillie Gifford & Co.
3.79872%
Tang Capital Management, LLC
Tang Capital Management, LLC
...

PureTech Health Executives and Management Board

JL

Dr. John Lamattina

(76)

Non-Executive Independent Director

Compensation290,000.00 USD
RL

Dr. Robert Langer

(76)

Co-Founder, Non-Executive Director

Compensation270,000.00 USD
SB

Ms. Sharon Barber-lui

(51)

Interim Independent Non-Executive Chairman of the Board

Compensation260,000.00 USD
KM

Ms. Kiran Mazumdar-Shaw

(72)

Non-Executive Independent Director

Compensation235,000.00 USD
MH

Dr. Michele Holcomb

(57)

Non-Executive Independent Director

Compensation123,653.00 USD

PureTech Health Supply Chain

PureTech Health Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
8 companies
#Name1M3M6M1Y2YTrend
1
BeiGene
Supplier
0.82
0.69
0.86
0.89
0.70
2
Invesco
Supplier
0.74
0.63
0.80
0.88
0.52
3
Teva Pharmaceutical Inds
Supplier
0.89
-0.10
-0.06
0.54
0.45
#Name1M3M6M1Y2YTrend
1
Vor Biopharma
Supplier
0.06
0.64
0.84
0.89
—
2
Roche Holding
0.90
-0.32
0.05
-0.36
-0.38
3
Bristol-Myers Squibb
Supplier
0.61
-0.64
-0.89
-0.62
-0.31
4
Eli Lilly
Supplier
0.62
-0.70
-0.60
-0.72
-0.15
5
Karuna Therapeutics
Supplier
0.84
-0.27
0.22
0.17
0.29

Frequently asked questions about PureTech Health

The business model of PureTech Health PLC revolves around identifying, selecting, and commercializing cutting-edge technologies and therapeutics in the healthcare industry. PureTech Health PLC focuses on transformative healthcare innovations in areas such as immune and inflammatory disorders, cognitive and behavioral disorders, and rare diseases. By leveraging its expertise and network of collaborations, PureTech Health PLC aims to develop and advance its pipeline of therapies through strategic partnerships, licensing deals, and subsidiary companies. This business model allows PureTech Health PLC to drive innovation and deliver impactful healthcare solutions to patients worldwide.

All fundamentals and in-depth analysis of PureTech Health

Our stock analysis for PureTech Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PureTech Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

PureTech Health Stock
PureTech Health Revenue→
PureTech Health Stock
PureTech Health Net Income→
PureTech Health Stock
PureTech Health P/E→
PureTech Health Stock
PureTech Health P/S→
PureTech Health Stock
PureTech Health EBIT→
PureTech Health Stock
PureTech Health Dividend→
PureTech Health Stock
PureTech Health Directors Dealings→
PureTech Health Stock
PureTech Health Stocks→
PureTech Health Stock
PureTech Health Market capitalization→
PureTech Health Stock
PureTech Health Debt→
PureTech Health Stock
PureTech Health Liabilities→
PureTech Health Stock
PureTech Health Equity→
PureTech Health Stock
PureTech Health AAQS→
PureTech Health Stock
PureTech Health Employees→
PureTech Health Stock
PureTech Health ROE→
PureTech Health Stock
PureTech Health ROA→
PureTech Health Stock
PureTech Health ROCE→
PureTech Health Stock
PureTech Health News→
PureTech Health Stock
PureTech Health Analyst Price Targets→